Eli Lilly and Co. and Adocia have entered a worldwide licensing collaboration for the development of an ultra-rapid insulin, known as BioChaperone Lispro, for the treatment of type 1 and type 2 diabetes. BioChaperone Lispro employs Adocia’s BioChaperone technology and is currently in Phase Ib trials. The companies will work to optimize glucose levels during and after meals. BioChaperone Lispro may provide greater flexibility in the timing of insulin injections, lower variability of post-m...